Metoclopramide, marketed under the brand name REGLAN®, is a small molecule drug that acts as a dopamine-2 (D2) antagonist.

OncoC4 Reveals Initial Participant with Late-Stage Prostate Cancer Receives Dose in Early to Mid-Stage Study for BNT316/ONC-392, a Collaborative Effort with BioNTech.

Hutchmed and Inmagene have exercised licensing options for two drug candidates, IMG-007 and IMG-004, as per their strategic collaboration agreement.

Absci Begins Preclinical Studies on ABS-101, a New Leading Candidate for an Anti-TL1A Antibody, Created and Enhanced with Advanced AI Design Tools.

Mupirocin, also known by its brand name CENTANY®, is a small molecule drug that works as an RNA synthetase inhibitor to treat bacterial infections.

STORM Therapeutics will showcase research on its innovative METTL1 tRNA Methyltransferase blockers at the ESMO event for specialized cancer treatments.

On Jan 25, 2024, the 2024 ASCO_GU reported results from suspending enzalutamide combo tx in high-risk BCR prostate cancer men.

FDA hastens assessment of a new application for Linvoseltamab, aimed at treating recurring or resistant forms of Multiple Myeloma.

Oxybutynin, marketed as DITROPAN®, is a medication approved by the US FDA in 1975 for the treatment of overactive bladder.

ReCode Therapeutics Reports Initial Dosing of Subjects in Phase 1 Trial for Inhaled mRNA Therapy, RCT2100, Aimed at Cystic Fibrosis Treatment.

Upadacitinib acts as an ATP-competitive JAK inhibitor; it competes with ATP and blocks nucleotide binding to inhibit kinase activity and the phosphorylation of downstream effectors.

Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development has initiated dosing in the early-stage ALETA-001 clinical study, targeting individuals with recurrent or unresponsive B-cell cancers.